CymaBay Therapeutics Inc. (CBAY) is set for a tempting yields with an average volume of 3.64M

investchronicle 86

CymaBay Therapeutics Inc. (CBAY) is priced at $5.95 after the most recent trading session. At the very opening of the session, the stock price was $5.71 and reached a high price of $6.04, prior to closing the session it reached the value of $5.66. The stock touched a low price of $5.60.

Recently in News on September 3, 2020, CymaBay Therapeutics to Present at Upcoming Investor Conferences. CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in three virtual investor conferences including Citi’s 15th Annual BioPharma Conference taking place September 9-10, 2020, the H.C. Wainwright 22nd Annual Global Investment Conference taking place September 14-16, 2020 and the Cantor Global Healthcare Conference taking place September 15-17, 2020. You can read further details here

CymaBay Therapeutics Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $7.09 on 08/10/20, with the lowest value was $1.21 for the same time period, recorded on 03/18/20.

CymaBay Therapeutics Inc. (CBAY) full year performance was -6.15%

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, CymaBay Therapeutics Inc. shares are logging -16.08% during the 52-week period from high price, and 391.74% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $1.21 and $7.09.

The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 1939238 for the day, which was evidently lower, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the CymaBay Therapeutics Inc. (CBAY) recorded performance in the market was 203.57%, having the revenues showcasing 56.99% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 430.01M, as it employees total of 24 workers.

Analysts verdict on CymaBay Therapeutics Inc. (CBAY)

During the last month, 10 analysts gave the CymaBay Therapeutics Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.

According to the data provided on, the moving average of the company in the 100-day period was set at 4.07, with a change in the price was noted +4.18. In a similar fashion, CymaBay Therapeutics Inc. posted a movement of +236.16% for the period of last 100 days, recording 4,046,634 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for CBAY is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.

CymaBay Therapeutics Inc. (CBAY): Technical Analysis

Raw Stochastic average of CymaBay Therapeutics Inc. in the period of last 50 days is set at 70.99%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 34.39%. In the last 20 days, the company’s Stochastic %K was 24.60% and its Stochastic %D was recorded 24.62%.

Let’s take a glance in the erstwhile performances of CymaBay Therapeutics Inc., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 203.57%. Additionally, trading for the stock in the period of the last six months notably improved by 286.36%, alongside a downfall of -6.15% for the period of the last 12 months. The shares increased approximately by -4.57% in the 7-day charts and went up by -13.77% in the period of the last 30 days. Common stock shares were driven by 56.99% during last recorded quarter.